Komori
Human Metabolome Technologies (6090) · InitiativeAdvanced

Initiation of Short-Term Borrowing to Lower the Cost of Capital

First written in FY2021-Q3. 2 of 4 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2022.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021-Q3 – FY2021AdvancedFY2022-Q3 – FY20222021: 220212022: 22022
Same theme, other companies
Flexible financing using short-term borrowings and credit facilitiesA theme 219 companies write about · 2 as a headwind · 202 as a tailwind

53 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 194 companies compared. The sentences above are computed from all 194.Comparing 200 of the theme's 225 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022AdvancedAnnual report

    「Net cash provided by financing activities was ¥80.491 million. This was mainly due to an increase of ¥100 million in short-term borrowings.」

    Short-term borrowings increased by a further ¥100 million, bringing the balance at the end of the period from ¥100 million to ¥200 million.
  2. FY2022-Q3AdvancedAnnual report

    「This resulted from decreases of ¥17.380 million in accounts payable and ¥16.302 million in provisions for losses on the liquidation of affiliated companies, together with increases of ¥100 million in short-term borrowings and ¥25.840 million in accrued income taxes, among other factors.」

    Short-term borrowings increased by ¥100 million, bringing the balance from ¥100 million at the end of the previous consolidated fiscal year to ¥200 million.
  3. FY2021RestatedAnnual report

    「The Group incurs funding needs for research and development of new services and businesses, the purchase of equipment enabling state-of-the-art measurement and analysis, and short-term working capital associated with fluctuations in demand. As a basic policy, the Group meets these needs for research and development investment, capital investment and working capital through shareholders’ equity, including cash and cash equivalents on hand.」

    The Company continues its policy of primarily using shareholders’ equity to fund research and development and capital investment, while using bank borrowings to fund capital investment and short-term working capital.
  4. FY2021-Q3First statedAnnual report

    「This resulted from the recognition of ¥100 million in short-term borrowings following the initiation of short-term borrowing from a bank to reduce the cost of capital, an increase of ¥20.550 million in the provision for bonuses accompanying the introduction of a new personnel system, and decreases of ¥51.194 million in accounts payable, ¥16.444 million in accrued income taxes and other liabilities included in other liabilities, including accrued consumption taxes and advances received.」

    The Company initiated short-term borrowing from a bank to reduce the cost of capital and recorded ¥100 million in short-term borrowings.
Moved together

"Expansion of Orders for the Metabolome Analysis Business" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Expansion of Orders for the Metabolome Analysis Business2×
  3. 2Proactive Promotional Activities and Acquisition of Large-Scale Projects2×
  4. 3Improvement in profitability of the metabolome analysis business2×
  5. 4Consolidated operating loss narrows, while ordinary and net losses widen2×
  6. 5Development of a New Service in the Metabolome Analysis Business2×
  7. 6Growth and Improved Profitability of the Metabolome Analysis Business2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Initiation of Short-Term Borrowing to Lower the Cost of Capital | Human Metabolome Technologies,Inc. (6090) | Komori